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The aims of this study were to determine if porcine circovirus type 2 (PCV2) vaccination of the dam is
effective in preventing fetal PCV2 infection and reproductive failure. Twelve pregnant, PCV2-naïve sows were
randomly divided into four groups, with three sows in each group. Group 1 sows served as noninoculated,
nonvaccinated negative controls, group 2 sows were vaccinated with a commercially available PCV2 vaccine at
28 days of gestation and were not inoculated, group 3 sows were vaccinated at 28 days of gestation and
inoculated with PCV2b at 56 days of gestation, and group 4 sows were inoculated with PCV2b but were not
vaccinated. Serum samples from all sows were collected weekly throughout the gestation period, and sows were
allowed to farrow naturally. At parturition, sow colostrum samples, presuckle serum samples, and tissues from
the piglets were collected. Reproductive failure was not observed under the study conditions. PCV2 vaccination
induced PCV2-specific immunoglobulin G and serum neutralizing antibodies in sows from groups 2 and 3 and
prevented detectable PCV2 viremia in the dams after challenge. In group 3, PCV2 DNA was detected in
colostrum samples, fetuses, and live-born pigs; however, microscopic lesions and PCV2-specific antigen were
not present in any of the fetuses in this group. The results from this study indicate that vertical transmission
of PCV2 can occur in PCV2-vaccinated dams.
Porcine circovirus type 2 (PCV2) is a nonenveloped, single-
stranded, circular DNA virus of approximately 1.7 kb and is
classified in the Circoviridae family, in the genus Circovirus
(38). PCV2 has three currently recognized genotypes, namely,
PCV2a, PCV2b, and PCV2c (4, 26). Multiple disease entities
are recognized with PCV2 infection in swine and include pneu-
monia, diarrhea, wasting, and reproductive failure (26). PCV-
associated disease (PCVAD) is used to describe the multisys-
temic disease manifestations related to PCV2 infection.
PCV2 was first described for growing high-health-status pigs
in Canada (9) and was later found to be associated with re-
productive disease in mature animals (24, 39). PCV2-associ-
ated reproductive failure was first reported in Canada. Clini-
cally, the cases were characterized by late-term abortions,
decreased numbers of viable piglets, and increased numbers of
stillborns and mummified fetuses (24, 39). Gross lesions of
PCV2-associated fetal infection included dilated cardiomyop-
athy, pulmonary edema, hepatomegaly, and ascites. The most
consistent microscopic changes associated with PCV2 infection
of fetuses include myocardial degeneration, necrosis, fibrosis,
and nonsuppurative myocarditis (39). These changes are due
to an apparent PCV2 tropism for fetal myocardiocytes (34).
However, this tropism diminishes in late gestation, and in-
creased levels of PCV2 DNA can be detected in lymphoid
tissues (33). In addition, PCV2 was found to be capable of
crossing the placenta and causing fetal infection in PCV2-
negative sows during viremia after intranasal inoculation (29).
It has been demonstrated that PCV2 inoculation of sows 3
weeks before parturition can result in lethargy, abortion, and
delivery of stillborn piglets as early as 7 days postinoculation
(29).
During 2004 and 2005, PCVAD in growing pigs spread rap-
idly throughout North America, resulting in severe disease
characterized by high morbidity, high mortality, and decreased
growth efficiencies. Molecular characterization of the PCV2
strains involved in these outbreaks identified PCV2b, which
had not been reported previously in North America (2). There-
after, multiple PCV2 vaccines became available for disease
prevention. However, an approved sow vaccine to protect
against PCV2-associated reproductive failure is not currently
available in the United States. The objective of this study was
to determine if PCV2 vaccination of the dam is effective in
preventing fetal PCV2 infection and reproductive losses.
MATERIALS AND METHODS
Animals and breeding. Twelve specific-pathogen-free, crossbred sows of uni-
form genetics were purchased from a single herd serologically negative for
PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), porcine
parvovirus (PPV), swine influenza virus (SIV), and encephalomyocarditis virus
(EMCV). All sows were synchronized for estrus detection by use of a commercial
product (Matrix; Intervet Inc., Millsboro, DE), using the manufacturer’s recom-
mended dose (15 mg/sow/day) and duration (15 days). Twenty hours after re-
moval, each sow received 5 ml of gonadotropin (P.G. 600; Intervet Inc., Mills-
boro, DE) intramuscularly and was then artificially inseminated with PCV2
DNA-free extended semen (28) for three consecutive days upon estrus detection.
Sow pregnancy was confirmed at 28 days of gestation by ultrasonography.
Experimental design and sample collection. The experimental protocol was
approved by the Iowa State University Institutional Animal Care and Use Com-
mittee. Sows were randomly divided into four groups of three sows each. All
groups were housed separately in a biosafety level 2 facility for the duration of
the study. Group 1 sows served as noninoculated and nonvaccinated controls.
Group 2 and 3 sows were vaccinated with a licensed, commercially available
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PCV2 vaccine at 28 days of gestation. At 56 days of gestation, all sows in groups
3 and 4 were inoculated oronasally with an infectious PCV2b stock. All sows were
allowed to farrow naturally.
Serum samples were collected from all sows prior to breeding and weekly
thereafter until parturition. At parturition, sow colostrum samples and live-born-
piglet presuckle serum samples were collected. All piglets and fetuses (stillborn
and mummified) from these sows were necropsied on the day of parturition.
Vaccination. Group 2 and 3 sows received 1 ml of a killed, baculovirus-
expressed, commercially available PCV2 vaccine (Ingelvac CircoFLEX; Boehr-
inger Ingelheim Vetmedica Inc.) intramuscularly in the neck at 28 days of
gestation. The PCV2 vaccine is labeled for administration to healthy pigs of more
than 3 weeks of age for the reduction of inflammation and lymphoid depletion
associated with PCV2 infection. The vaccine was stored according to the man-
ufacturer’s instructions until use.
Inoculation. Sows from groups 3 and 4 were inoculated oronasally with 5 ml
(2.5 ml per nostril) of PCV2b stock (strain NC-16485) (18) with an infectious
titer of approximately 104.2 50% tissue culture infective doses per ml at 56 days
of gestation. The PCV2b stock was produced by transfecting PK-15 cells with an
infectious clone as previously described (7), and the titer of the PCV2b stock was
determined by using an immunofluorescence assay with a PCV2-specific anti-
body (7). The PCV2 inoculum was stored at 80°C until inoculation.
Clinical assessment. All sows were visually monitored weekly for clinical signs
of PCV2-associated disease, including weight loss, diarrhea, and dyspnea. In
addition, sows from groups 2 and 3 were visually monitored for 2 h following
vaccination for adverse reactions. Sows from groups 3 and 4 were monitored
daily for pyrexia, lethargy, and vaginal discharge for 2 weeks following inocula-
tion at 56 days of gestation.
Serology. Live-born-piglet presuckle serum samples, sow colostrum samples,
and sow serum samples, collected prior to insemination and at 28, 56, 84, and 112
days of gestation, were tested for anti-PCV2 antibodies, using a recombinant
PCV2 capsid protein-based enzyme-linked immunosorbent assay (ELISA) as
described previously (23). Samples having a sample-to-positive-control (S/P)
ratio of 0.2 were considered to be positive. The S/P ratio for each sample was
calculated by dividing the sample optical density at 450 nm by the positive control
optical density. The sensitivity and specificity of the PCV2 ELISA used in this
study were previously determined to be 79.9% and 99.6%, respectively, for a
cutoff value of 0.2 (23).
The presence of anti-PCV2 neutralizing antibodies was assessed in all sow
serum samples collected from all groups at 56 and 112 days of gestation, using a
fluorescence focus neutralization assay performed according to the standard
operating procedure at the Iowa State University Veterinary Diagnostic Labo-
ratory (32). PCV2 isolate ISU-98-15237 was used in the assay.
In addition, sow serum samples collected on day 112 of gestation were tested
for the presence of anti-PRRSV antibodies by ELISA (IDEXX Laboratories,
Inc., Westbrook, ME), anti-SIV H1N1 and H3N2 antibodies by ELISA (IDEXX
Laboratories, Inc., Westbrook, ME), anti-PPV antibodies by hemagglutination
inhibition (21), and anti-EMCV antibodies by virus neutralization (protocol
number BPPRL2109; National Veterinary Service Laboratory, Ames, IA).
PCR. Sow serum samples, colostrum samples, and live-born-piglet presuckle
sera were tested by quantitative real-time PCR for the presence and amount of
PCV2 DNA (27). DNA extraction was carried out using a commercially available
DNA extraction isolation kit (QIAamp DNA Mini kit; Qiagen, Valencia, CA)
according to the manufacturer’s recommendations. The quantitative real-time
PCR parameters, primers, and probes were as described previously (27).
Necropsy and microscopic examination. Hearts, lungs, livers, kidneys, brains,
spleens, tonsils, thymuses, and pinnae (ear notches) were collected from all
live-born and stillborn piglets. A similar set of tissues was collected from mum-
mified fetuses if postmortem tissue identification was possible at necropsy. Pla-
cental samples from the dams were also obtained at parturition. Tissue sections
were placed in 10% neutral buffered formalin, allowed to fix completely, em-
bedded in paraffin wax, cut into 4-m-thick sections, and stained with hematox-
ylin and eosin. Stained tissues were evaluated for the presence of microscopic
lesions, such as inflammation and lymphoid depletion, in a blinded fashion by a
veterinary pathologist.
IHC. Immunohistochemical (IHC) staining was performed on selected tissue
sections (myocardium, lungs, pinnae, tonsils, and placenta), using a polyclonal
rabbit anti-PCV2 serum for the detection of PCV2 antigen as described previ-
ously (37).
Statistical analysis. Summary statistics for all groups were calculated to assess
the overall quality of the data. Repeated data measurements (sow PCR and
serology) were log transformed and analyzed using multivariate analysis of vari-
ance (multivariate ANOVA) to detect significant differences over time. If dif-
ferences were significant (P  0.05), a nonparametric one-way ANOVA
(Kruskal-Wallis test) was used to analyze the data at each time point, followed
by pairwise comparisons using the Wilcoxon rank sum test. For nonrepeated
measures (piglet viremia, piglet anti-PCV2 antibodies, colostral antibodies, and
colostral PCV2 DNA), a nonparametric Kruskal-Wallis one-way ANOVA fol-
lowed by pairwise comparisons using the Wilcoxon rank sum test was used.
Statistical analysis was performed using JMP 7.0.2 (SAS Institute, Cary, NC).
RESULTS
Clinical assessment and farrowing. Adverse vaccine reac-
tions were not observed in group 2 and 3 sows following vac-
cination. Clinical disease (pyrexia, lethargy, wasting, diarrhea,
dyspnea, vaginal discharge, or abortion) associated with PCV2
infection was not observed during gestation in group 3 and 4
sows. All sows maintained pregnancy and farrowed at 114 to
116 days postinsemination. Table 1 summarizes litter charac-
teristics by group.
Serology. All sows were negative for anti-PCV2 antibodies
prior to insemination and seronegative for PRRSV, SIV
(H1N1 and H3N2), PPV, and EMCV at parturition. Group 1
sows (negative controls) remained negative for anti-PCV2 an-
tibodies for the duration of the study. Table 2 summarizes sow
anti-PCV2 antibody development by group at 28, 56, 84, and
112 days of gestation. All sows in groups 2, 3, and 4 had
detectable anti-PCV2 antibodies at 112 days of gestation. A
significant effect of time (P  0.027) was observed for the
production of anti-PCV2 antibodies; however, differences be-
tween groups were not observed.
PCV2 neutralizing antibodies were identified in all group 2,
3, and 4 sows during gestation, whereas group 1 sows remained
seronegative for PCV2 (Table 2). A significant effect of time
(P  0.001) was observed for serum neutralizing antibody
production; however, significant group differences were not
observed at 56 and 112 days of gestation.
Colostrum-associated anti-PCV2 antibodies were present in
all group 2, 3, and 4 sows but were not detected in group 1 sows
(Table 3). A significant statistical difference was not observed
between groups (P  0.05).
Anti-PCV2 immunoglobulin G (IgG) antibodies were not
detected in presuckle sera collected from group 1, 2, and 4
TABLE 1. Summary of expelled piglets and fetuses by litter and
group at parturition for nonvaccinated and noninoculated sows
(group 1), sows vaccinated at 28 days of gestation (groups 2
and 3), and sows oronasally inoculated with PCV2b
(groups 3 and 4) at 56 days of gestation
Group Sow no.
No. of piglets or fetuses
Total
born Live-born Stillborn Mummified
1 1 11 10 1 0
2 10 9 1 0
3 16 14 2 0
2 4 18 14 2 2
5 12 11 1 0
6 13 11 0 2
3 7 15 12 2 1
8 19 17 0 2
9 16 16 0 0
4 10 12 11 0 1
11 14 14 0 0
12 10 10 0 0
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live-born piglets. Conversely, two live-born piglets in group 3
(from the same litter) had detectable anti-PCV2 antibodies,
with S/P ratios of 0.26 and 0.47 (Table 4).
PCV2 DNA detection by PCR. PCV2 DNA was not detected
by quantitative real-time PCR amplification in weekly serum
samples collected from group 1, 2, or 3 sows prior to artificial
insemination or during gestation. In contrast, two of three
group 4 sows developed detectable PCV2 viremia during ges-
tation. PCV2 viremia in group 4 sows first appeared at 70 days
of gestation. Sows remained PCV2 viremic for four to seven
consecutive weeks, and one of three sows had detectable PCV2
DNA in serum at parturition. Significant differences in sow
viremia were not observed between groups (P  0.05) (data
not shown).
Colostrum samples collected at parturition were negative for
PCV2 DNA for groups 1 and 2. In contrast, PCV2 DNA was
detected in two of three group 3 sows and three of three group
4 sows (Table 3). The amount of PCV2 DNA present in co-
lostrum of group 4 sows (mean log PCV2 genomic copies/ml
colostrum) was significantly (P  0.042) higher than that ob-
served for group 3 (Table 3).
Presuckle sera collected from group 1 and 2 live-born piglets
did not contain PCV2 DNA. PCV2 DNA was detected in sera
from group 3 and group 4 live-born piglets (Table 4). Group 3
live-born viremic piglets originated from two different litters
(one and two piglets).
Macroscopic lesions, microscopic examination, and IHC. At
necropsy, no gross lesions were observed in live-born piglets or
stillborns from group 1, 2, 3, or 4 sows. Furthermore, no mi-
croscopic tissue changes associated with PCV2 infection or
PCV2 antigen were detected in live-born piglets, stillborns, or
mummified fetuses from group 1, 2, or 3 sows or in examined
placental sections. However, one live-born piglet from a group
4 sow had mild multifocal myocardial degeneration and necro-
sis (Table 4), with lymphoid depletion in the tonsils and spleen.
In this piglet, moderate to abundant amounts of PCV2 antigen
were detected in the myocardium and tonsils, as determined by
IHC stains (Table 4).
DISCUSSION
PCV2-associated viremia in the dam is the most likely source
of fetal infection (29, 30), though semen transmission appears
to be a possible route (13, 14, 17, 18, 19, 35). Previous exper-
imental studies proved that PCV2 is capable of crossing the
placenta in naïve sows after intranasal inoculation during late
gestation (29). In the current study, oronasal PCV2 inoculation
resulted in detectable viremia, development of anti-PCV2 an-
tibodies, and the presence of PCV2 DNA in colostrum samples
of group 4 (unvaccinated) sows. PCV2 viremia of the dam
resulted in transplacental infection of fetuses in utero, con-
firming the potential of vertical transmission of PCV2 infec-
tion. In contrast to other experimental and field observations
of PCV2-associated reproductive failure (11, 24, 29, 31, 39),
abortion, dam illness, and increased numbers of nonviable
piglets were not observed under the conditions of this study.
Differences between studies may be related to differences in
the amount or virulence of the PCV2 isolate used for inocu-
lation. However, our findings suggest that vertical PCV2 trans-
mission in the field could occur at a higher incidence than what
has been reported.
In recent years, multiple PCV2 vaccines have become avail-
able to combat PCVAD. Currently, three vaccines are licensed
for growing pigs of 3 to 4 weeks of age or older, and another
vaccine is labeled for prefarrowing usage on dams. In a PCV2
vaccination study involving 72 growing animals, vaccination
prevented detectable PCV2-associated viremia and reduced
PCV2 fecal and oral shedding of viral DNA (8). In another
experimental study, vaccination induced neutralizing antibod-
ies and reduced PCV2 viremia, fecal shedding, and PCV2-
associated microscopic lesions (25). Similar observations were
made during field investigations involving PCV2-vaccinated
and nonvaccinated pigs (6, 10, 15).
To date, the performance of only one PCV2 vaccine has
been studied experimentally with breeding animals. Sow vac-
cination reduced the number of stillborn piglets at parturition,
TABLE 2. Prevalence and sow-associated mean group levels of anti-PCV2 IgG and serum neutralizing antibodies for nonvaccinated and
noninoculated sows (group 1), sows vaccinated at 28 days of gestation (groups 2 and 3), and sows oronasally inoculated with
PCV2b (groups 3 and 4) at 56 days of gestation
Group
No. of sows with IgG antibody/no. of sows in group (mean S/P ratio  SE) on day of gestation
No. of sows with neutralizing antibody/
no. of sows in group (mean antibody
levela  SE) on day of gestation
28 56 84 112 56 112
1 0/3 (0.00 0.00) 0/3 (0.00  0.00) 0/3 (0.00  0.00) 0/3 (0.00  0.00) 0/3 (1.81  0.00) 0/3 (1.81  0.00)
2 0/3 (0.00 0.00) 2/3 (0.29  0.15) 2/3 (0.28  0.11) 3/3 (0.56  0.05) 3/3 (2.31  0.20) 3/3 (2.41  0.00)
3 0/3 (0.00 0.00) 2/3 (0.08  0.15) 2/3 (0.29  0.15) 3/3 (0.43  0.11) 2/3 (2.11  0.30) 3/3 (2.51  0.10)
4 0/3 (0.00 0.00) 0/3 (0.00  0.00) 1/3 (0.23  0.21) 3/3 (0.40  0.12) 0/3 (1.81  0.00) 3/3 (2.81  0.44)
a Mean log-transformed serum neutralizing antibody level.
TABLE 3. Prevalence of anti-PCV2 IgG antibodies and PCV2
DNA in colostrum of nonvaccinated and noninoculated sows
(group 1), sows vaccinated at 28 days of gestation (groups 2
and 3), and sows oronasally inoculated with PCV2b
(groups 3 and 4) at 56 days of gestation
Group
No. of positive animals/total no. of animals (mean S/P
ratio SE or log-transformed PCV2 DNA level SE)
PCV2 antibodies PCV2 DNAa
1 0/3 (0.00  0.00) 0/3 (0.00  0.00)A
2 3/3 (0.75  0.22) 0/3 (0.00  0.00)A
3 3/3 (0.49  0.12) 2/3 (2.41  1.20)A
4 3/3 (0.50  0.14) 3/3 (4.68  1.15)B
a Different superscripts within the column indicate significant (P  0.05) dif-
ferences in group mean PCV2 DNA amounts.
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decreased prewean piglet mortality, improved sow mortality,
and improved farrowing rates (1, 3, 5, 12, 16, 36). Vaccination
was found to be successful in reducing PCV2-associated repro-
ductive failure and improving sow performance under field
conditions. However, to our knowledge, the effect of sow vac-
cination on fetal PCV2 replication in utero has not been in-
vestigated to date.
Detectable differences in the immune response following
vaccination of pregnant animals and differences in immune
regulation in the uterus during pregnancy have been reported
(22, 40). In the current study, sows were vaccinated after con-
firmation of pregnancy due to the limited availability of PCV2-
naïve sows. PCV2 vaccination of pregnant animals had no
detectable adverse effects when the vaccine was administered
at 28 days of gestation, eliminated detectable PCV2 viremia,
and induced both serum neutralizing antibodies and colostral
anti-PCV2 antibodies. However, vaccination did not prevent
the presence of PCV2 DNA in colostral samples, fetal PCV2
viremia, or the development of anti-PCV2 IgG antibodies in
piglets following PCV2 challenge at 56 days of gestation. Pos-
sible considerations for the lack of PCV2 viremia in group 3
sows include a limited detection rate due to the timing of
serum collection (weekly) and the sensitivity of the PCR assay.
Interestingly, live-born group 3 piglets that were viremic or had
anti-PCV2 antibodies at birth did not have detectable PCV2
antigen in tissues (myocardium, lungs, tonsils, or pinnae). This
suggests that either fetal infection occurred later in gestation
than that in group 4 piglets or dam vaccination reduced fetal
PCV2 replication.
Although PCV2 vaccination in this report did not prevent
fetal infection, two group 3 piglets developed specific anti-
PCV2 antibodies in utero without having detectable presuckle
viremia, microscopic lesions associated with fetal infection, or
detectable PCV2 antigen in tissue. This implies that immuno-
competent fetuses (70 days of gestation) are able to clear
infection prior to parturition without associated microscopic
lesions or detectable PCV2 antigen. This observation has not
been reported previously and is similar to the case for PPV
infection in fetal swine (20).
In summary, PCV2 infection of naïve pregnant sows may not
result in reproductive failure but can be associated with fetal
infection. PCV2 vaccination of pregnant sows induced neutral-
izing and anti-PCV2 antibodies in serum and colostrum but did
not prevent vertical transmission. Sow vaccination also did not
prevent colostral shedding of PCV2, which can be another
route of vertical transmission. Furthermore, a proportion of
fetuses infected in utero were able to clear PCV2 infection
prior to parturition.
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